A disease registry may serve as a more suitable data source for evaluation of factor VIII inhibitors in pediatric patients receiving orphan drug treatment for hemophilia A compared with a single-arm clinical trial. While several new factor VIII products have been developed in recent years, the rarity of hemophilia A...
treatment News
NEW YORK, NY – The World Health Organization on Tuesday reported growing HIV drug resistance against GSK and ViiV Healthcare’s antiretroviral medication Tivicay (dolutegravir), noting that observational and survey data suggest that resistance may now be higher than levels observed in clinical trials. Results from four surveys placed resistance rates...
YONGIN, South Korea — GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of “GC1109”, an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug Safety (MFDS). ‘GC1109’ contains protective...
TORONTO, Canada – Theralase Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (” PDCs “) for the safe and effective destruction of various cancers, bacteria and viruses is providing an update regarding its Phase II Non-Muscle Invasive...
TORONTO, Canada – Theralase® Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (PDCs) for the safe and effective destruction of various cancers, bacteria and viruses, has been granted a Canadian patent for a new cancer vaccine....
A clinical trial at the National Institutes of Health found that a medication, denosumab, significantly reduced abnormal bone turnover in adults with fibrous dysplasia, a rare disease marked by weak and misshapen bones. Bone turnover, a process in which old bone is continuously replaced with new bone, is unusually accelerated...
MONTREAL, Canada — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced completion of enrollment of the first six participants in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer. Sudocetaxel...
DUBLIN, Ireland — Theravance Biopharma Inc. today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The PIFR-2 study aimed to demonstrate greater improvement in lung function for YUPELRI...
ROCKVILLE, Md. — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of enrollment as planned into VIRAGE, a multinational, Phase 2b, randomized,...
ROCKVILLE, Md. — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline data from the investigator sponsored Phase 1 trial conducted by collaborators at Sant Joan de Déu-Barcelona Children’s Hospital (SJD)....